Results 31 to 40 of about 204,688 (384)

Case report: Cyclosporine A-induced extrapyramidal syndrome following hematopoietic stem cell transplantation

Frontiers in Neurology, 2023
IntroductionCyclosporine A-associated neurotoxicity has been reported in up to 40% of patients and its wide range of neurological adverse effects have been reported, ranging from mild tremors to fatal leukoencephalopathy.
Fatema Al-Amrani, Abdulhakeem Al Rawas, Eiman Al-Ajmi, Amna Al Futaisi   +3 more
doaj   +1 more source

De novo donor‐specific antibodies in belatacept‐treated vs cyclosporine‐treated kidney‐transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT‐EXT studies

American Journal of Transplantation, 2018
Donor‐specific antibodies (DSAs) are associated with an increased risk of antibody‐mediated rejection and graft failure. In BENEFIT and BENEFIT‐EXT, kidney‐transplant recipients were randomized to receive belatacept more intense (MI)–based, belatacept ...
Robert A. Bray, H. Gebel, Robert M. Townsend, M. Roberts, M. Polinsky, L. Yang, H. Meier-Kriesche, C. P. Larsen   +7 more
semanticscholar   +1 more source

Factors associated with cardiovascular events after simultaneous liver–kidney transplant from the US Multicenter Simultaneous Liver–Kidney Transplant Consortium

Hepatology Communications, EarlyView., 2022
Abstract Cardiovascular disease is a leading complication after both liver and kidney transplantation. Factors associated with and rates of cardiovascular events (CVEs) after simultaneous liver–kidney transplant (SLKT) are unknown. This was a retrospective cohort study of adult SLKT recipients between 2002 and 2017 at six centers in six United Network ...
Jennifer Jo, Gonzalo Crespo, Dyanna Gregory, Jasmine Sinha, Jiaheng Xie, Min Zhang, John Magee, Pranab Barman, Yuval A. Patel, Aaron Schluger, Kara Walters, Scott Biggins, Natalia Filipek, Giuseppe Cullaro, Randi Wong, Jennifer C. Lai, Gabriel J. Perreault, Elizabeth C. Verna, Pratima Sharma, Lisa B. VanWagner   +19 more
wiley   +1 more source

Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine

Case Reports in Gastroenterology, 2021
Medical rescue therapy for patients with severe steroid-refractory ulcerative colitis (UC) consists of intravenous (IV) cyclosporine or infliximab and remains limited.
Alicia Philippou, Anam Rizvi, Adam Steinlauf   +2 more
doaj   +1 more source

Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases

Allergy, Asthma & Clinical Immunology, 2023
Background While both the AAAAI/ACAAI and the EAACI/GA2LEN/EuroGuiDerm/APAAACI guidelines recommend starting cyclosporine for patients with chronic urticaria who have had an inadequate response to omalizumab, many clinicians are hesitant to initiate ...
Anthony F. LaCava, Olajumoke O. Fadugba
doaj   +1 more source

Pure White Cell Aplasia and Immune Thrombocytopenia after Thymoma Resection: A Case Report and Review of the Literature

Case Reports in Hematology, 2022
We report a case of pure white cell aplasia (PWCA) postthymoma resection in a 74-year-old male presenting with a 2-week history of fevers, night sweats, and severe febrile neutropenia.
Michael Youssef, Tyler W. Stratton, Reid C. Gallant, Christine Young, Daniel Y. Li, Siavash Piran   +5 more
doaj   +1 more source

A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis

Journal of Inflammation Research, 2018
Background Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are dermatologic emergencies with high morbidity and mortality risk. Cyclosporine, an immunomodulatory agent, is sometimes used off-label, and its role continues to be debated.
Q. Ng, Michelle Lee Zhi Qing De Deyn, Nandini Venkatanarayanan, Collin Yih Xian Ho, W. Yeo   +4 more
semanticscholar   +1 more source

Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis

Journal of International Medical Research, 2023
Objective To conduct a meta-analysis assessing the efficacy and safety of cyclosporine-based combinations for primary immune thrombocytopenia (ITP).
Xiaojing Li, Wenwei Zhu, Jizhang Bao, Jiekai Li, Yongming Zhou   +4 more
doaj   +1 more source

Cyclosporine Biosynthesis in Tolypocladium inflatum Benefits Fungal Adaptation to the Environment

mBio, 2018
The cyclopeptide cyclosporin A was first isolated from the filamentous fungus Tolypocladium inflatum showing antifungal activity and was later developed as an immunosuppressant drug. We report the biosynthetic mechanism of cyclosporines that are mediated
Xiu-qing Yang, P. Feng, Ying Yin, Kathryn E. Bushley, J. Spatafora, Chengshu Wang   +5 more
semanticscholar   +1 more source

Long‐Term Outcomes in Belatacept‐ Versus Cyclosporine‐Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT‐EXT, a Phase III Randomized Study

American Journal of Transplantation, 2016
In the Belatacept Evaluation of Nephroprotection and Efficacy as First‐Line Immunosuppression Trial–Extended Criteria Donors (BENEFIT‐EXT), extended criteria donor kidney recipients were randomized to receive belatacept‐based (more intense [MI] or less ...
Antoine Durrbach, J. M. Pestana, S. Florman, M. Rial, Lionel Rostaing, Dirk Kuypers, A. J. Matas, T. Wekerle, M. Polinsky, H. Meier‐Kriesche, S. Munier, J. Grinyo   +11 more
semanticscholar   +1 more source